This base-editing is an advanced version of CRISPR technology. “A few years ago this would have been science fiction,” said UCL’s Prof Waseem Qasim. She had not responded to standard therapies, such as chemotherapy or a first bone marrow transplant, and her family had been discussing palliative care options before the research opportunity was proposed. Dr Rob Chiesa, study investigator and bone marrow transplant consultant at GOSH said: “Although most children with T-cell leukaemia will respond well to standard treatments, around 20% may not. “My ultimate goal is to become a research scientist and be part of the next big discovery that can help people like me.”Main image: National Cancer Institute